# GLAND (GLAND) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/gland

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,969.1
- Change: +2.11%
- As of: 2026-09-18
- 1D return: +1.86%
- 5D return: +0.51%
- 1M return: +5.03%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, GLAND is trading at ₹2961.9, maintaining a bullish technical stance across daily, weekly, and monthly timeframes. All observed timeframes show the price trading above key moving averages (20-day, 50-day, 200-day) and the Supertrend indicator, reinforcing the prevailing uptrend. The weekly timeframe exhibits strong upward momentum, indicated by a rising ADX of 51.48 and a positive Supertrend direction.

Nearest support is observed at ₹2959.23, a level just below the current price. Resistance is noted around ₹3010.67, approximately 1.65% higher. The stock's recent activity includes 4 positive attention events in the last 30 days, with no downside events. The current setup carries a risk profile characterized by an annualized volatility of 32% and a current drawdown of -2%. A recent "Hammer" pattern was observed on the weekly chart on September 18, 2026.

Key watch conditions include monitoring the price action around the immediate support at ₹2959.23. A sustained break below this level could signal a short-term pullback. Conversely, a move above the nearest resistance at ₹3010.67, especially with increased volume, would reinforce the bullish trend. Investors should also watch for any significant shifts in the ADX or Supertrend direction across timeframes.

- Current price as of September 18, 2026: ₹2961.9.
- Bullish trend confirmed across daily, weekly, and monthly timeframes, with price above key moving averages and Supertrend.
- Nearest support level identified at ₹2959.23.
- Nearest resistance level identified at ₹3010.67.
- Watch for price action around ₹2959.23 support and ₹3010.67 resistance for trend confirmation or potential shifts.

- Hammer
- Doji
- Harami
- Bearish Engulfing Reversal
- Bullish Engulfing Reversal

### News Context

On September 17, 2026, Gland Pharma was mentioned in a report detailing bulk deals across several companies. Prasid Uno Family Trust reduced its stake by 1.7% in Entero Healthcare Solutions, while Chiratae Growth Fund sold a 1.25% stake in Rentomojo. Gland Pharma was listed alongside these entities in the context of these transactions. Separately, the broader Indian pharmaceutical sector showed positive movement, with the Nifty Pharma Index rising 1.66% on the same day, snapping a five-day losing streak. This sector performance occurred within a generally positive market, with the Sensex and Nifty trading higher, though cautious sentiment persisted due to potential US interest rate hikes.

- On September 17, 2026, Gland Pharma was noted in a report on bulk deals involving other companies.
- The Nifty Pharma Index increased by 1.66% on September 17, 2026, ending a five-day decline.
- The broader market, including the Sensex and Nifty, traded positively on September 17, 2026.
- Market sentiment on September 17, 2026, was influenced by potential US interest rate hikes, leading to caution in certain segments.

- Prasid Uno Family Trust cuts stake by 1.7% in Entero Healthcare; Chiratae Growth Fund sells 1.25% stake in Rentomojo
- Quick Wrap: Nifty Pharma Index rises 1.66%
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak

### What Changed

As of September 18, 2026, Gland Pharma's share price has seen a modest increase, trading at ₹2961.9 compared to its previous price of ₹2907.8. This movement occurred within a broader market context where the Nifty Pharma Index rose by 1.66%. While the company's stock experienced a daily price change, the provided evidence does not indicate any new filings or specific news directly impacting Gland Pharma's operations. However, a news report from September 18, 2026, mentioned Gland Pharma in the context of bulk deals involving other entities like Entero Healthcare Solutions and Rentomojo, though no specific transaction details for Gland Pharma were detailed.

- On September 18, 2026, Gland Pharma's stock price was ₹2961.9, up from ₹2907.8.
- The Nifty Pharma Index increased by 1.66% on September 18, 2026.
- A news report on September 18, 2026, listed Gland Pharma among companies involved in bulk deals, alongside Entero Healthcare Solutions and Rentomojo.

- Prasid Uno Family Trust cuts stake by 1.7% in Entero Healthcare; Chiratae Growth Fund sells 1.25% stake in Rentomojo
- Quick Wrap: Nifty Pharma Index rises 1.66%

### Official Filings

Gland Pharma Limited's Board of Directors approved the acquisition of 100% equity in Gland Pharma USA Inc. (Gland US) from Gland Pharma International Pte. Ltd for a cash consideration of USD 5,01,208. This acquisition, expected to be completed by October 31, 2026, aims to streamline the corporate structure by making Gland US a direct wholly-owned subsidiary. Gland US reported nil turnover for the fiscal year ending March 31, 2026. Additionally, on September 13, 2026, the company's ESOP Compensation Committee approved the grant of 590,249 employee stock options under the ESOP 2025 scheme to 124 employees. These options have a three-year vesting schedule starting September 13, 2027, with exercise prices set at INR 1,461.15 for a portion and INR 1 for the remainder.

- On September 13, 2026, Gland Pharma's Board approved the acquisition of Gland Pharma USA Inc. for USD 5,01,208 cash.
- The acquisition of Gland Pharma USA Inc. is expected to be completed by October 31, 2026.
- On September 13, 2026, 590,249 employee stock options were granted to 124 employees under the ESOP 2025 scheme.
- The granted employee stock options have a three-year vesting schedule commencing September 13, 2027.
- Gland Pharma scheduled investor meetings between September 11, 2026, and September 25, 2026, with various financial institutions.

- Gland Pharma Limited has informed the Exchange about Board comments on fines levied by the Exchanges |SUBJECT: General Updates
- Gland Pharma Limited has informed the Exchange about Options to purchase securities |SUBJECT: Options to purchase securities
- Gland Pharma Limited has informed the Exchange about Allotment of 44,193 Equity Shares on exercise of ESOPs |SUBJECT: General Updates
- Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 13, 2026. |SUBJECT: Outcome of Board Meeting
- Gland Pharma Limited has informed the Exchange about acquisition of 100% of the equity share capital of Gland Pharma USA Inc. , a wholly-owned step down subsidiary of the Company, from Gland Pharma International Pte. Ltd, a wholly-owned subsidiary of the Company |SUBJECT: General Updates
- GLAND PHARMA LIMITED has informed the Exchange regarding Acquisition (including agreement to acquire) |SUBJECT: Acquisition (including agreement to acquire)-XBRL
- Gland Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- GLAND PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Gland Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Gland Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates

### Fundamentals

Gland Pharma's recent operating performance shows a mixed trend across its reported quarters. Revenue from operations saw an increase from ₹1,695.36 crore in Q3 FY2025-26 to ₹1,800.27 crore in Q1 FY2026-27. However, this revenue growth did not consistently translate into higher profitability. Profit Before Exceptional Items And Tax, after rising to ₹505.80 crore in Q4 FY2025-26, decreased to ₹434.98 crore in Q1 FY2026-27. Similarly, Profit Loss For Period From Continuing Operations followed a similar pattern, increasing from ₹261.48 crore in Q3 FY2025-26 to ₹366.68 crore in Q4 FY2025-26, before declining to ₹316.96 crore in Q1 FY2026-27. The company's expenses also fluctuated, increasing in Q1 FY2026-27 to ₹1,426.52 crore after a dip in Q4 FY2025-26. Investors may want to monitor the drivers behind the fluctuating profitability despite revenue increases and the trend in operating expenses.

- Revenue from operations increased from ₹1,695.36 crore in Q3 FY2025-26 to ₹1,800.27 crore in Q1 FY2026-27.
- Profit Before Exceptional Items And Tax decreased from ₹505.80 crore in Q4 FY2025-26 to ₹434.98 crore in Q1 FY2026-27.
- Profit Loss For Period From Continuing Operations declined to ₹316.96 crore in Q1 FY2026-27 from ₹366.68 crore in Q4 FY2025-26.
- Expenses rose to ₹1,426.52 crore in Q1 FY2026-27, compared to ₹1,348.46 crore in Q4 FY2025-26.

### Bull Case

Gland Pharma's technical indicators suggest a constructive market setup as of September 18, 2026. The stock is trading above key moving averages, with its daily and monthly Supertrend indicators signaling a bullish trend. This is supported by positive momentum, as indicated by the rising EMA and SMA slopes across daily and weekly timeframes. The company has also demonstrated significant returns over various periods, notably a year-to-date return of 0.73 and a 6-month return of 0.78, indicating strong recent performance. While the stock is approaching resistance levels, the current technical posture suggests upward momentum.

- The daily Supertrend indicator is 'bullish' as of September 18, 2026.
- The monthly Supertrend indicator is 'bullish' as of September 18, 2026.
- The year-to-date return was 0.73 as of September 18, 2026.
- The 6-month return was 0.78 as of September 18, 2026.

- Prasid Uno Family Trust cuts stake by 1.7% in Entero Healthcare; Chiratae Growth Fund sells 1.25% stake in Rentomojo
- Quick Wrap: Nifty Pharma Index rises 1.66%
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak

### Bear Case

While the company's technical indicators show a bullish trend across daily, weekly, and monthly timeframes, with the Supertrend indicator suggesting an upward direction, a cautious approach may be warranted due to the proximity to resistance levels. The stock is trading near its nearest resistance level at ₹3010.67, which is 1.65% above the current price. Further resistance is noted at ₹3040.9 (2.67% higher) and ₹3080.23 (4.0% higher). The presence of these resistance levels suggests potential challenges for further upward price movement.

- Nearest resistance level identified at ₹3010.67, 1.65% above the current price.
- Additional resistance levels observed at ₹3040.9 (2.67% higher) and ₹3080.23 (4.0% higher).
- The stock is trading close to these resistance points as of 2026-09-18.

- Prasid Uno Family Trust cuts stake by 1.7% in Entero Healthcare; Chiratae Growth Fund sells 1.25% stake in Rentomojo
- Quick Wrap: Nifty Pharma Index rises 1.66%
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak

### FAQs

**What recent corporate actions has Gland Pharma undertaken?**

On September 13, 2026, Gland Pharma's Board approved the acquisition of 100% equity of Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd for a cash consideration of USD 5,01,208. Gland Pharma USA Inc. is a step-down wholly-owned subsidiary. The company also approved the grant of 590,249 employee stock options to 124 employees under the ESOP 2025 scheme, with exercise prices of INR 1,461.15 and INR 1, vesting over three years starting September 13, 2027. Additionally, 44,193 equity shares were allotted on the exercise of ESOPs.

**How has Gland Pharma's stock performed over different periods?**

As of September 18, 2026, Gland Pharma has shown varied returns across different timeframes. The year-to-date (YTD) return is 0.73, and the return over the last 6 months is 0.78. The stock has also seen a return of 0.34 over the last 3 months and 0.47 over the last year. Returns over shorter periods include 0.04 for 1 month, 0.01 for 5 days, and 0.02 for 10 days and 1 day.

**What are the key technical indicators suggesting about Gland Pharma's current trend?**

On a daily timeframe, Gland Pharma's technical indicators suggest a bullish trend. The Supertrend is at 2709.41, indicating bullishness. The Exponential Moving Average (EMA) 20 is at 2887.87 and the Simple Moving Average (SMA) 20 is at 2900.03, both above the closing price of 2961.9. The EMA 50 is at 2736.37 and the SMA 50 is at 2723.95. The Average Directional Index (ADX) is 32.15, suggesting a strong trend. On a monthly timeframe, the Supertrend is at 1976.35, also indicating a bullish trend, with the EMA 20 at 2090.47 and SMA 20 at 1975.86.

**What are the nearest support and resistance levels for Gland Pharma's stock?**

As of September 18, 2026, the nearest support level is at 2959.23, which is 0.09% below the current price. Other support levels are identified at 2889.67, 2838.23, and 2789.55. The nearest resistance level is at 3010.67, which is 1.65% above the current price. Additional resistance levels are noted at 3040.9 and 3080.23.

- Prasid Uno Family Trust cuts stake by 1.7% in Entero Healthcare; Chiratae Growth Fund sells 1.25% stake in Rentomojo
- Quick Wrap: Nifty Pharma Index rises 1.66%
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Gland Pharma Limited has informed the Exchange about Board comments on fines levied by the Exchanges |SUBJECT: General Updates
- Gland Pharma Limited has informed the Exchange about Options to purchase securities |SUBJECT: Options to purchase securities
- Gland Pharma Limited has informed the Exchange about Allotment of 44,193 Equity Shares on exercise of ESOPs |SUBJECT: General Updates
- Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 13, 2026. |SUBJECT: Outcome of Board Meeting
- Gland Pharma Limited has informed the Exchange about acquisition of 100% of the equity share capital of Gland Pharma USA Inc. , a wholly-owned step down subsidiary of the Company, from Gland Pharma International Pte. Ltd, a wholly-owned subsidiary of the Company |SUBJECT: General Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹2,889.67
- Risk regime: Price Risk Currently Contained

### Support levels
- 2789.55
- 2181.9
- 1698.6203125

### Resistance levels
- 3040.9
- 3010.6666666666665
- 3080.233333333333

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +1.86% |
| return_10 | +1.86% |
| return_1m | +3.61% |
| return_1y | +46.88% |
| return_20 | +5.03% |
| return_3m | +34.50% |
| return_5 | +0.51% |
| return_6m | +77.91% |
| return_since_start | +63.63% |
| return_ytd | +72.70% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -26.74% |
| annualized_volatility | +31.56% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Growth Continues, but Sequential Profit Declines as Costs Rise Faster

Gland Pharma’s revenue increased to ₹1,800.27 crore in Q1 FY2026-27, up 3.3% from the previous quarter and 19.6% from the same quarter last year. Net profit, however, fell 13.6% sequentially to ₹316.96 crore, as expenses grew faster than revenue. Compared to the prior year, profit improved 47.1%, supported by revenue growth and a lower expense ratio.

## Revenue and Expense Trends

Revenue grew both sequentially and year-over-year. The sequential increase of ₹57.48 crore (3.3%) was smaller than the year-over-year increase of ₹294.65 crore (19.6%). Expenses rose 5.8% sequentially to ₹1,426.52 crore, outpacing the 3.3% revenue growth. As a result, the expense-to-revenue ratio increased from 77.4% in Q4 FY2025-26 to 79.2% in the current quarter. On a year-over-year basis, expenses grew 14.1% while revenue grew 19.6%, so the expense ratio improved from 83.0% in Q1 FY2025-26 to 79.2% in the current quarter.

## Profitability and Margins

Profit before tax (PBT) decreased 14.0% sequentially to ₹434.98 crore, and net profit decreased 13.6% to ₹316.96 crore. The sequential decline in profit occurred despite higher revenue, reflecting the faster rise in expenses. The PBT margin fell from 29.0% in Q4 to 24.2% in Q1, and the net profit margin fell from 21.0% to 17.6%. Year-over-year, margins expanded: PBT margin was 20.8% in Q1 FY2025-26 and net profit margin was 14.3%, both lower than the current quarter’s margins. No exceptional items were reported in the current or previous quarter.

## Non-Operating Items

Finance costs decreased to ₹4.36 crore from ₹10.03 crore in the previous quarter, a 56.5% decline. This reduction helped partially offset the overall expense growth, though the absolute amount remains small relative to total expenses. Other comprehensive income (OCI) swung from a gain of ₹100.91 crore in Q4 to a loss of ₹26.72 crore in Q1, a negative movement of ₹127.63 crore. This large swing does not affect operating profit but impacts total comprehensive income.

## Earnings Per Share

Basic earnings per share (EPS) decreased from ₹22.26 in Q4 to ₹19.23 in Q1, a decline of 13.6%. Year-over-year, EPS increased from ₹13.08 to ₹19.23, a 47.1% rise. Diluted EPS followed the same pattern, moving from ₹22.23 to ₹19.22 sequentially. The EPS movements align directly with the changes in net profit.

## Management Commentary

Gland Pharma reported a strong Q1FY27 with revenue up 20% YoY to ₹18,003 Mn and PAT up 47% YoY to ₹3,170 Mn, driven by successful execution of its CDMO strategy and resilient B2B model. Management highlighted growth from recent product launches (e.g., Dalbavancin, Multi-Vitamin) and strong customer demand across diversified product mix. The CDMO business contributed 50% of revenue, growing 20% YoY, while B2B grew 19% YoY. The US market led with 32% YoY growth, supported by volume expansion in Enoxaparin, Vancomycin, and Heparin.

Looking ahead, management expects sustainable long-term growth through a robust CDMO pipeline, including investments in differentiated technologies and capacity expansions. Key growth drivers include a CDMO partnership with a global pharma company (potential ~USD 90-100M annualized revenue from CY2029), a $644M RTU bag portfolio opportunity, and 15 co-development products expected to commercialize in FY28. R&D spending was ₹772 Mn (4% of revenue), focused on complex product development. Risks include volume decline in other core markets (Canada, Australia, NZ down 28% YoY) and reliance on timely tech transfers and approvals.

## Key Takeaway

Gland Pharma’s Q1 FY2026-27 results show significant year-over-year revenue and profit growth, but the sequential decline in profit from the prior quarter marks a shift in momentum. The faster growth in expenses relative to revenue sequentially compressed margins, while the year-over-year comparison shows a lower expense ratio. The large swing in other comprehensive income and the decline in finance costs were non-operating factors. Overall, the quarter demonstrates substantial year-over-year growth, while the sequential cost increase reverses the margin improvement seen in the previous quarter.

### Ratios

## Official filings

- 2026-09-13 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_13092026152419_Board_Comments_Fines.pdf)
- 2026-09-13 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_13092026153314_ESOPGrant13092026-SE_intimation.pdf)
- 2026-09-13 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_13092026153820_ESOPAllotment_13092026.pdf)
- 2026-09-13 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_13092026162446_BMOutcome_13092026_Final.pdf)
- 2026-09-13 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_13092026163744_BMOutcome_13092026_Final.pdf)
- 2026-09-13 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_18003_WebXMLFile_20260913_163918527.xml)
- 2026-09-10 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_10092026174324_Analyst_Institutional_Investor_Meet_17092026.pdf)
- 2026-09-08 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_18003_WebXMLFile_20260908_194928934.xml)
- 2026-09-08 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_08092026194223_Analyst_Institutional_Investor_Meet_11092026.pdf)
- 2026-09-04 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_04092026145307_Analyst_Institutional_Investor_Meet_09092026.pdf)
- 2026-09-04 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_18003_WebXMLFile_20260904_145522004.xml)
- 2026-09-01 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_01092026154914_USFDA_VSEZ_01092026NIL.pdf)
- 2026-08-31 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_31082026175549_Analyst_Institutional_Investor_Meet_03092026.pdf)
- 2026-08-31 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_18003_WebXMLFile_20260831_175759953.xml)
- 2026-08-26 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_26082026135817_Voting_Results_AGM_FY26_Final.pdf)
- 2026-08-26 — Regulatory Filing: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/RESULT_VOTING_1717983_26082026020512_WEB.xml)
- 2026-08-25 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_25082026222610_48th_AGM_Proceedings_Final.pdf)
- 2026-08-23 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_18003_WebXMLFile_20260823_094018497.xml)
- 2026-08-23 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_23082026092939_Analyst_Institutional_Investor_Meet_26082026.pdf)
- 2026-08-17 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_17082026130108_Earningscall_TranscriptQ1FY27_Final.pdf)
- 2026-08-17 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_18003_WebXMLFile_20260817_130414703.xml)
- 2026-08-14 — Management Change: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/GLAND_14082026084203_CEO_Final_Disclosure.pdf)
- 2026-08-14 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_18003_WebXMLFile_20260814_124132619.xml)
- 2026-08-10 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_18003_WebXMLFile_20260810_220704716.xml)
- 2026-08-10 — Generic Announcement: Gland Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_18003_WebXMLFile_20260810_171404277.xml)

## News and market events

- 2026-09-17 — MONEYCONTROL: **Prasid Uno Family Trust cuts stake by 1.7% in Entero Healthcare; Chiratae Growth Fund sells 1.25% stake in Rentomojo** — Bulk Deals,Entero Healthcare Solutions,Rentomojo,Karamtara Engineering,Gland Pharma — [Source](https://www.moneycontrol.com/news/business/markets/prasid-uno-family-trust-cuts-stake-by-1-7-in-entero-healthcare-chiratae-growth-fund-sells-1-25-stake-in-rentomojo-14032380.html)
- 2026-09-17 — BUSINESS: **Quick Wrap: Nifty Pharma Index rises 1.66%** — Powered by Capital Market - Live News — [Source](https://www.business-standard.com/markets/capital-market-news/quick-wrap-nifty-pharma-index-rises-1-66-126091700943_1.html)
- 2026-09-17 — BUSINESS: **Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak** — The Feds indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction. — [Source](https://www.business-standard.com/markets/capital-market-news/sensex-nifty-trade-in-positive-terrain-pharma-shares-snap-5-day-losing-streak-126091700646_1.html)
- 2026-09-10 — MONEYCONTROL: **Fosun sale raises questions, but brokerages back Gland Pharma growth outlook** — Gland Pharma, Fosun, divestment, share sale, CDMO — [Source](https://www.moneycontrol.com/news/business/fosun-sale-raises-questions-but-brokerages-back-gland-pharma-growth-outlook-14027091.html)
- 2026-09-07 — BUSINESS: **Gland Pharma Ltd gains for third straight session** — Gland Pharma Ltd is quoting at Rs 2974.6, up 1.44% on the day as on 12:49 IST on the NSE. The stock is up 58.38% in last one year as compared to a 4.12% jump in NIFTY and a 21.48% jump in the Nifty Pharma index. — [Source](https://www.business-standard.com/markets/capital-market-news/gland-pharma-ltd-gains-for-third-straight-session-126090700516_1.html)
- 2026-09-06 — FREEPRESSJOURNAL.IN: **Gland Pharma Stake Sale: Fosun Pharma Sells 4.55% For Rs 2,121 Crore, Holding Falls Below 50%** — Fosun Pharma sold a 4.55 percent stake in Gland Pharma for Rs 2,121.50 crore, reducing its holding to 47.22 percent. — [Source](https://www.freepressjournal.in/business/gland-pharma-stake-sale-fosun-pharma-sells-455-for-rs-2121-crore-holding-falls-below-50)
- 2026-09-05 — MONEYCONTROL: **Fosun Pharma sells 4.5% stake in Gland Pharma for Rs 2,121 crore** — Fosun Pharma, Gland Pharma, Fosun Pharma stake sale, Gland Pharma block deal, Gland Pharma shares, Fosun Pharma Gland Pharma stake, Gland Pharma shareholding, Kotak Mahindra Mutual Fund, Axis Mutual Fund, ICICI Prudential Mutual Fund, Gland Pharma Q1 results, Gland Pharma net profit, Gland Pharma revenue, pharma stocks, block deals, Fosun Pharmaceutical — [Source](https://www.moneycontrol.com/news/business/markets/fosun-pharma-sells-4-5-stake-in-gland-pharma-for-rs-2-121-crore-14023452.html)
- 2026-09-05 — The Hindu: **Fosun Pharma sells 4.5% stake in Gland Pharma for Rs 2,121 crore** — The transaction marks the second major stake sale by Fosun Pharma in the pharmaceutical company in a little over two years — [Source](https://www.thehindubusinessline.com/markets/stock-markets/fosun-pharma-sells-45-stake-in-gland-pharma-for-rs-2121-crore/article71433130.ece)
- 2026-09-04 — Economic Times: **Gland Pharma block deal: Fosun Pharma divests 99 lakh shares worth Rs 2,800 crore** — Fosun Pharma sold a 6% stake in Gland Pharma for ₹2,800 crore via a block deal, reducing its holding to 45.77%. Major buyers included Kotak, Axis, and ICICI Prudential Mutual Funds, while Gland Pharma shares closed higher at ₹2,932.40. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/gland-pharma-block-deal-fosun-pharma-divests-99-lakh-shares-worth-rs-2800-crore/articleshow/133768263.cms)
- 2026-09-04 — BUSINESS: **Volumes jump at HBL Engineering Ltd counter** — HBL Engineering Ltd saw volume of 127.24 lakh shares by 14:14 IST on NSE, a 20.33 fold spurt over two-week average daily volume of 6.26 lakh shares — [Source](https://www.business-standard.com/markets/capital-market-news/volumes-jump-at-hbl-engineering-ltd-counter-126090400643_1.html)
- 2026-09-04 — CNBC-TV18: **Gland Pharma shares fall after ₹2,100 crore block deal; Promoter likely seller** — On Thursday, CNBC-TV18 reported, citing sources that Fosun Pharma was likely to sell up to 5% of its stake in the company for ₹2,279.5 crore. The floor price had been set at ₹2,763 per share, sources said. — [Source](https://www.cnbctv18.com/market/gland-pharma-share-price-block-deal-2279-crore-promoter-fosun-likely-seller-buyer-shareholding-returns-19983812.htm)
- 2026-09-02 — BUSINESS: **Sai Life Science surges 8% in two days; stock hits new high in weak market** — In the past month, Sai Life Science stock surged 19 per cent, against a 2.8 per cent decline in the BSE Sensex. — [Source](https://www.business-standard.com/markets/news/sai-life-science-surges-8-in-two-days-stock-hits-new-high-in-weak-market-126090200295_1.html)
- 2026-09-02 — BUSINESS: **Stock Alert: Hero MotoCorp, NMDC, Gland Pharma, Wipro** — Shares of LIC Housing Finance and SAIL are banned from F&O trading on 2 September 2026. — [Source](https://www.business-standard.com/markets/capital-market-news/stock-alert-hero-motocorp-nmdc-gland-pharma-wipro-126090200142_1.html)
- 2026-09-02 — CNBC-TV18: **These are the three Pharma stocks that should be on your radar today** — All the three Pharma stocks in focus today, Gland Pharma, Caplin Point and Nephrocare Health, have risen between 50% to 70% so far this year. — [Source](https://www.cnbctv18.com/market/pharma-stocks-today-caplin-point-gland-pharma-nephrocare-health-services-share-price-usfda-gmp-acquisition-impact-19981919.htm)
- 2026-09-02 — BUSINESSTODAY: **Top stocks in news: Wipro, Hero Moto, NMDC, Welspun Corp, Adani Green, Annu Projects, Gland Pharma** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, Wipro, Hero MotoCorp, NMDC, Welspun Corp, Adani Green Energy, Annu Projects, Gland Pharma, L&T Finance, Texmaco Rail & Engineering, Ashiana Housing, Ujjivan Small Finance Bank, ARSS Infrastructure Projects, Sical Logistics — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-wipro-hero-moto-nmdc-welspun-corp-adani-green-annu-projects-gland-pharma-552700-2026-09-02)
- 2026-09-02 — Mint: **Stocks to watch today: Reason why these shares are in focus for Wednesday's trading session | Full list** — Stock market today: Benchmark indices Sensex and Nifty closed marginally lower on Tuesday amid concerns over elevated crude oil prices and renewed tensions between the US and Iran, which weighed on investor sentiment. — [Source](https://www.livemint.com/market/stock-market-news/stocks-to-watch-today-reason-why-these-shares-are-in-focus-for-wednesdays-trading-session-full-list-11788311231011.html)
- 2026-09-01 — CNBC-TV18: **Stocks to Watch for September 2: Reliance Industries, Adani Green, NMDC and more** — From Reliance Industries to Ujjivan Small Finance Bank, here are the key stocks to track ahead of Wednesday’s trading session. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-september-2-reliance-industries-adani-green-nmdc-and-more-19981541.htm)
- 2026-09-01 — The Hindu: **Sensex today | Stock Market Highlights: Sensex ends 12 pts down, Nifty closes at 24,055 on higher crude prices; banks, autos lead losses** — Sensex, Nifty, Share Prices Highlights: Indian shares edged lower on ​Tuesday as escalating Middle East tensions pushed oil prices and ‌bond yields higher, while heavyweight banks reversed Monday's ​closing auction gains. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-highlights-1st-september-2026/article71412225.ece)
- 2026-08-26 — BUSINESSTODAY: **Piper Serica exits CDSL, CAMS shares; adds Gland Pharma, Astra Microwave** — Piper Serica, Abhay Agarwal, Piper Serica portfolio, CDSL shares, CAMS shares, Gland Pharma shares, Astra Microwave shares, Gland Pharma, Astra Microwave Products, PMS, small cap stocks, pharma stocks, EMS stocks, stock market, portfolio changes, investment strategy — [Source](https://www.businesstoday.in/markets/stocks/story/piper-serica-exits-cdsl-cams-shares-adds-gland-pharma-astra-microwave-551518-2026-08-26)
- 2026-08-14 — Mint: **Pulse of the Street: Tata jitters, metal rout weigh on Indian equities** — Indian equities fell 0.8% this week as Tata succession uncertainty and a sell-off in metals outweighed gains in telecom and realty stocks, leaving India behind a broader AI-led rally across Asia. — [Source](https://www.livemint.com/market/stock-market-news/pulse-of-the-street-tata-jitters-metal-rout-weigh-on-indian-equities-11786708624550.html)
- 2026-08-14 — CNBC-TV18: **Gland Pharma appoints Dr. Reddy’s Deepak Sapra as CEO; stock hits 52-week high** — Gland Pharma shares rose over 1% after Deepak Sapra was named CEO. He will take charge on November 16, 2026. The company also reported a 47.1% jump in Q1 FY27 net profit. — [Source](https://www.cnbctv18.com/market/gland-pharma-appoints-dr-reddys-labs-deepak-sapra-as-ceo-q1-results-profit-revenue-shares-rise-19969341.htm)
- 2026-08-14 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty recovers from lows; Welspun Living up 10%** — Sensex Today | Stock Market LIVE Updates: The markets are under pressure, with the Nifty index falling towards the 24,300 mark. The Nifty Bank is also trading on similar ground, falling below the 57,500 mark. Tata Motors PV, Hindalco, Max Health are the top losers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-sensex-hdfc-bank-nifty-bank-q1-earnings-tata-motors-max-fin-defence-bdl-share-price-liveblog-19969121.htm)
- 2026-08-14 — The Hindu: **Sensex today | Stock Market Live: Sensex, Nifty open lower as West Asia tensions offset easing Fed rate hike bets** — Sensex, Nifty, Share Prices LIVE: Indian equities opened with a cautious bias on Friday as investors weighed easing expectations of a September US rate hike against persistent West Asia tensions, continued foreign selling and weekly losses, while softer crude prices offered some relief. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-14th-august-2026/article71341547.ece)
- 2026-08-11 — Economic Times: **Gland Pharma shares rally 12% after Q1FY27 profit jumps 47% YoY. Should you buy, sell or hold?** — Gland Pharma shares rose sharply after Q1FY27 profit rose 47% and revenue grew 20% year-on-year. While strong margins and CDMO growth prompted Elara Securities to raise its earnings estimates, the brokerage downgraded the stock to ‘Accumulate from ‘Buy after its 40% three-month rally, citing limited near-term upside. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/gland-pharma-shares-rally-12-after-q1fy27-profit-jumps-47-yoy-should-you-buy-sell-or-hold/articleshow/133142679.cms)
- 2026-08-11 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty falls below 24,450; market extends losses** — Sensex Today | Stock Market LIVE Updates: We are in the second half of this expiry session, and the bears are relentless. The markets are still under pressure, with the Nifty falling close to a 130 points, falling below the 24,450 mark. The Nifty Bank is under pressure, falling over 400 points, falling to 57,300. IndiGo, Tata Consumer and Axis Bank are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-expiry-today-oil-adani-bse-wipro-vedanta-vodafone-idea-rvnl-share-price-liveblog-19966134.htm)

## Business profile

**Strategic vision:** Manufactures and markets complex generic injectables globally.

### Business segments
- **Sterile Injectables:** The company is active in sterile injectables, focusing on complex products including NCE-1s, First-to-File products, and 505(b)(2) filings.
- **Oncology:** Gland Pharma is active in the oncology therapeutic segment, focusing on complex injectables.
- **Ophthalmic:** Gland Pharma is active in the ophthalmic therapeutic segment, focusing on complex injectables.

### Competitive strengths
- Expertise in pharmaceutical research and development, manufacturing, and marketing of complex injectables.
- Global supply chain reaching over 60 countries, including key regulated markets.
- Capabilities in developing niche products through complex molecule synthesis and diverse delivery systems.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/gland
Markdown representation: https://faxioms.com/stocks/gland?render=md